LY3556050 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Peripheral Neuropathic Pain
Conditions
Diabetic Peripheral Neuropathic Pain
Trial Timeline
May 6, 2021 → Jun 13, 2022
NCT ID
NCT04707157About LY3556050 + Placebo
LY3556050 + Placebo is a phase 2 stage product being developed by Eli Lilly for Diabetic Peripheral Neuropathic Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT04707157. Target conditions include Diabetic Peripheral Neuropathic Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06074562 | Phase 2 | Completed |
| NCT04874636 | Phase 2 | Completed |
| NCT04707157 | Phase 2 | Terminated |
| NCT04627038 | Phase 2 | Completed |
| NCT05341102 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetic Peripheral Neuropathic Pain